Carregant...
Access to Investigational Drugs: FDA Expanded Access Programs or “Right‐to‐Try” Legislation?
PURPOSE: The Food and Drug Administration Expanded Access (EA) program and “Right‐to‐Try” legislation aim to provide seriously ill patients who have no other comparable treatment options to gain access to investigational drugs and biological agents. Physicians and institutions need to understand the...
Guardat en:
| Publicat a: | Clin Transl Sci |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4503515/ https://ncbi.nlm.nih.gov/pubmed/25588691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12255 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|